Clinical Utility
Clinical utility concerns whether using a test or model leads to worthwhile effects on care compared with a relevant alternative.
#Utility concerns the consequences of using a result
BEST describes clinical utility as a conclusion about net improvement in health outcomes or useful information for diagnosis, treatment, management or prevention, including possible benefits and risks to individuals and populations. CDC's ACCE framework treats utility as distinct from analytic and clinical validity.
Read what change the test or tool is meant to produce. A technically accurate result or a clinical association does not establish a worthwhile consequence of using it. Utility is about a specified use, not an unlimited property of a product.
Evidence: FDA-NIH BEST: analytical validation, clinical validation and utility / CDC archive: ACCE genetic-test evaluation framework
#Follow the path from result to action
The historical ACCE questions ask how a positive or negative genetic-test result affects care, whether an effective remedy or acceptable action exists, and whether people have access to it. They also ask about downstream health risks, personnel, facilities, education and monitoring.
Read whether a result can lead to an appropriate action in the setting being studied, rather than stopping at diagnostic performance. A proposed benefit can fail to reach people if the next step is unavailable or unusable. These questions illustrate an evaluation framework, not a claim that every test requires the same action pathway.
Evidence: CDC archive: questions for genetic-test validity and utility
#Benefits need to be considered alongside burdens
BEST includes benefits and risks in the utility concept. ACCE asks about follow-up risks and financial costs. The proposed V3 framework for digital measurements also notes accessibility, compatibility, burden and ease of use as factors in determining fitness for purpose.
Read the effects of testing and subsequent action, including who experiences the burdens. More measurements or earlier information are not automatically better outcomes. The digital framework is a contextual example, not proof that usability testing alone establishes improved health outcomes.
Evidence: FDA-NIH BEST: analytical validation, clinical validation and utility / CDC archive: questions for genetic-test validity and utility / Goldsack et al. (2020): proposed digital-measurement validation framework
#A usefulness claim needs its scope and evidence
BEST emphasizes that validation concerns an intended purpose and that evidence sufficient for one purpose may not establish another. ACCE includes ethical, legal and social implications alongside validity and utility rather than treating performance as the only evaluation question.
Read the claimed benefit, population, setting and alternative against which the tool is being considered. Unknown utility is not the same as proven lack of benefit; it means the claim remains unsettled by the available evidence. Mynd has performed no clinical-utility study or product assessment here.
Evidence: FDA-NIH BEST: validation and intended purpose / CDC archive: ACCE genetic-test evaluation framework
Source note
The sections above were checked against the linked sources. No clinical review has been performed. This is general research education, not a clinical guideline.